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Effects of rituximab dose on 
hepatitis B reactivation in patients 
with resolved infection undergoing 
immunologic incompatible kidney 
transplantation
Juhan Lee1,4, Jun Yong Park  2, Deok Gie Kim1,4, Jee Youn Lee1,4, Beom Seok Kim3, 
Myoung Soo Kim1,4, Soon Il Kim1,4, Yu Seun Kim1,4 & Kyu Ha Huh1,4
Sensitized patients received desensitization therapy with rituximab for kidney transplantation. 
However, the impact of rituximab dose on hepatitis B virus (HBV) reactivation is unknown. Patients 
who underwent living donor kidney transplantation between 2008 and 2016 were grouped according to 
rituximab dose (control vs. standard-dose rituximab [375 mg/m2] vs. reduced-dose rituximab [200 mg/
body]) for comparison of HBV reactivation. A total of 336 hepatitis B surface antigen (HBsAg)-negative/
antibody to hepatitis B core antigen (anti-HBc)-positive patients underwent kidney transplantation, 
of whom 91 (27.1%) received rituximab for desensitization (57 standard-dose and 34 reduced-dose 
rituximab). During the study period, eight patients experienced HBV reactivation (three in the control 
group, five in the standard-dose group). In the standard-dose group, four patients experienced hepatitis 
flare, and one patient died due to hepatic failure. No HBV reactivation occurred in the reduced-dose 
group. Standard-dose rituximab significantly decreased hepatitis B surface antigen antibody titer 
(anti-HBs; −99.8 IU/L) at 12 months, compared with reduced-dose rituximab (−20.1 IU/L) and control 
(−39.1 IU/L, P = 0.017). Standard-dose rituximab (HR, 10.60; 95% CI, 2.52–44.60; P = 0.001) and 
anti-HBs < 100 IU/L at transplantation (HR, 9.06; 95% CI, 1.11–74.30; P = 0.04) were independent risk 
factors for HBV reactivation. Standard-dose rituximab significantly increased HBV reactivation risk for 
HBsAg-negative/anti-HBc-positive kidney transplant patients.
Hepatitis B virus (HBV) infection is the common chronic viral infection in the world1. Although the preva-
lence is decreasing as a result of vaccination, roughly 30% of the world’s population shows serological evidence 
of resolved HBV infection (hepatitis B surface antigen [HBsAg]-negative/antibody to hepatitis B core antigen 
[anti-HBc]-positive). Although safe and effective antiviral drugs are available to prevent HBV reactivation, fatal 
HBV reactivations have occurred in resolved HBV patients, particularly after receiving rituximab therapy2–4.
In kidney transplant, desensitization with rituximab allows patients who are sensitized to human leukocyte 
antigen or blood antigen to overcome the immunologic barrier5,6. When introduced in the transplant setting, 
the rituximab standard dose (375 mg/m2) was based on the treatment of lymphoma7. The effect of reduced ritux-
imab doses (10–300 mg/m2) has been tested sufficiently on splenic and peripheral blood B cells8. In addition, a 
Japanese group reported favorable long-term outcomes of ABO-incompatible (ABOi) kidney transplantation 
with a reduced dose of rituximab (a fixed dose of 200 mg)9. Thereafter, many transplant centers began to use 
reduced doses of rituximab to improve safety and cost-effectiveness.
Dose intensity of rituximab has previously been found to be an important risk factor for HBV reactivation in 
patients with hematologic malignancy10. In the transplant setting, however, rituximab is generally administered as 
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a single course with different doses11. Although more than 20% of kidney transplant recipients receive rituximab 
for desensitization, only limited data regarding rituximab dose and subsequent HBV reactivation are available for 
this population12,13. Consequently, we directly compared the impact of rituximab dose on HBV reactivation after 
kidney transplantation.
Results
Patients. A total of 957 patients underwent living donor kidney transplantation between 2008 and 2016. 
Of them, 365 (38.1%) were HBsAg-negative/anti-HBc-positive at the time of transplantation. During the study 
period, 262 patients received kidney transplantation without rituximab desensitization and 91 received rituximab 
desensitization. Of the 262 patients who did not receive rituximab, 17 were excluded due to the use of rituximab 
post-transplant (Fig. 1).
Baseline characteristics. Baseline characteristics of patients are presented in Table 1. There were no signifi-
cant differences in age or dialysis among the groups; however, the proportion of female patients and re-transplant 
cases, and the mean number of human leukocyte antigen mismatches were significantly higher in the standard- 
and reduced-dose rituximab groups than in the control group. However, there were no significant differences 
in sex, re-transplant, and mean number of HLA mismatches between standard- and reduced-dose rituximab 
groups. Sero-positivity of anti-HBs (≥10 IU/L) and donor anti-HBc were comparable among the groups; 







(n = 34) P-value
Age (years) 50.0 ± 10.4 49.6 ± 7.9 54.0 ± 8.3 0.072
Female, n (%) 75 (30.6%) 24 (42.1%) 18 (52.9%) 0.017
Duration of dialysis (months) 15.4 ± 30.4 22.0 ± 42.9 14.6 ± 22.3 0.367
HLA mismatch number 2.9 ± 1.5 3.7 ± 1.6 3.5 ± 1.3 <0.001
Retransplantation, n (%) 10 (4.1%) 10 (17.5%) 7 (20.6%) <0.001
Anti-HBs positive (≥10 IU/L), n (%) 209 (85.3%) 50 (87.7%) 30 (88.2%) 0.827
  Anti-HBs ≥ 100 IU/L, n (%) 113 (46.1%) 33 (57.9%) 10 (29.4%) 0.03
Donor anti-HBc positive, n (%) 84 (34.3%) 20 (35.1%) 8 (23.5%) 0.438
Induction agents <0.001
  Basiliximab, n (%) 243 (99.2%) 49 (86.0%) 21 (61.8%)
  ATG, n (%) 2 (0.8%) 8 (14.0%) 13 (38.2%)
ATG for anti-rejection 9 (3.7%) 8 (14.0%) 1 (2.9%) 0.226
Maintenance CNI 0.001
  Tacrolimus, n (%) 192 (78.4%) 55 (96.5%) 32 (94.1%)
  Cyclosporin, n (%) 53 (21.6%) 2 (3.5%) 2 (5.9%)
Trough level of tacrolimus (at 1 year) 5.6 ± 3.0 5.2 ± 3.2 5.8 ± 1.9 0.563
Trough level of tacrolimus (at 2 year) 5.0 ± 1.9 5.2 ± 3.7 5.8 ± 3.0 0.281
Number of plasmapheresis — 3.96 ± 3.23 4.24 ± 4.26 0.248
Median follow-up (months) 74 [44.5, 99] 65 [48, 78.5] 31.5 [17.8, 40] <0.001
Table 1. Baseline characteristics.
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however, there was a significant difference in the proportion of anti-HBs ≥100 IU/L, which was significantly 
lower in the reduced-dose rituximab group. The use of ATG for induction was significantly more common for 
patients in the reduced- and standard-dose rituximab group than for patients in the control group, but the use 
of ATG for anti-rejection therapy was not significantly different among the groups. The use of cyclosporin for 
maintenance immunosuppression was significantly more common in the control group than in the other groups. 
In the standard-dose rituximab group (375 mg/m2), mean dose of rituximab was 600 mg, which was three times 
that of the reduced-dose rituximab group (200 mg). Median follow-up times for the control, standard-dose, and 
reduced-dose rituximab groups were 74, 65, and 31.5 months, respectively. The date of last patient follow-up was 
December 15, 2017.
HBV reactivation. During the study period, eight patients experienced HBV reactivation. Of these, five cases 
occurred in the standard-dose rituximab group (5/57, 8.8%), and three cases occurred in the control group (3/245, 
1.2%). However, no HBV reactivation occurred in the reduced-dose rituximab group. In the standard-dose ritux-
imab group, the median time from rituximab desensitization to HBV reactivation was 11 months (range, 5–22 
months). For the three patients with HBV reactivation, the median time from kidney transplantation to HBV 
reactivation was 48 months (range, 24–57 months). With respect to the pre-transplant anti-HBs titers in patients 
with HBV reactivation, seven patients had low titers of anti-HBs (<100 IU/L), whereas one patient had a high 
titer of anti-HBs (≥100 IU/L).
Clinical outcomes. The clinical features of the eight patients with HBV reactivation are listed in Table 2. Five 
patients (A–E) received a single dose of rituximab 2–7 days before kidney transplantation. At the time of HBV 
reactivation, all patients received maintenance therapy with a triple immunosuppressant regimen consisting of 
tacrolimus, prednisone, and mycophenolate mofetil (MMF). Two patients (C and E) were treated for acute rejec-
tion 21 and 8 months prior to HBV reactivation, respectively. Among the five patients described, four experienced 
hepatitis flare (serum ALT >100 IU/L) at the time of HBV reactivation.
Three patients (F–H) in the control group experienced HBV reactivation. All three patients received mainte-
nance therapy with tacrolimus and prednisone. Two of these patients also received MMF, and the other patient 
received mTOR inhibitor therapy as well. None of the patients received anti-rejection therapy prior to HBV reac-
tivation. Among the three patients, one experienced hepatitis flare at the time of HBV reactivation.
All patients initiated entecavir upon detection of reactivation. One patient in the standard-dose rituximab 
group (patient B) died of hepatic failure despite active antiviral treatment. Another patient in the standard-dose 
rituximab group (patient D) died due to unknown causes 20 months after HBV reactivation.
Risk factors for HBV reactivation. Factors associated with HBV reactivation were analyzed using a Cox 
regression model. As shown in Table 3, anti-HBs < 100 IU/L at the time of transplantation and standard-dose 
rituximab for desensitization were significant independent risk factors for HBV reactivation. The causes of ritux-
imab (ABO incompatible, positive crossmatch, or high PRA) were not associated with HBV reactivation.
During the study period, 15 patients of the standard-dose rituximab group (26.3%) and 8 patients of the 
reduced-dose rituximab group (23.5%) received plasmapheresis ± intravenous immunoglobulin for treatment 
of antibody-mediated rejection (AMR, P = 0.767). AMR treatment was not associated with HBV reactivation.
The cumulative rates of HBV reactivation, depending on rituximab desensitization and anti-HBs status, are 
shown in Fig. 2.
Anti-HBs levels during follow-up. The changes in anti-HBs levels from pre-transplant measurement and 
1-year after transplantation are shown in Fig. 3. Overall, anti-HBs titers decreased during the first year after trans-
plantation regardless of treatment group. At 1-year after kidney transplantation, the mean changes in anti-HBs 
between the standard-dose rituximab, reduced-dose rituximab, and control groups were −99.8, −20.1, and −39.1 
IU/L, respectively (P = 0.017). Post-hoc analysis indicated that standard-dose rituximab significantly reduced the 
anti-HBs titer.
The mean numbers of plasmapheresis sessions were similar between the standard- and reduced-dose ritux-


















A M 48 265.65 375 mg/m2 (ABOi) 11 >1.7 × 108 641 Alive with functioning graft
B M 59 13.56 375 mg/m2 (ABOi) 5 >1.7 × 108 340 Death due to liver failure
C M 48 52.08 375 mg/m2 (XM+) ACR 22 1.23 × 107 39 Alive with functioning graft
D M 61 Negative (3.99) 375 mg/m2 (ABOi) 5 >1.7 × 108 524 Death due to unknown causes
E M 51 Negative (0.63) 375 mg/m2 (XM+) AMR 12 4.94 × 107 237 Alive with functioning graft
F M 61 Negative (1.22) No 24 >1.7 × 108 213 Alive with functioning graft
G M 60 10.91 No 48 5.22 × 107 52 Alive with functioning graft
H M 49 73.59 No 57 5.32 × 107 50 Alive with functioning graft
Table 2. Clinical outcomes of HBV reactivation.
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standard-dose rituximab group and 8/34 patients in the reduced-dose rituximab group). Evaluation of the impact 
of plasmapheresis (five or more sessions) on anti-HBs titers revealed no difference between the groups.
Discussion
Rituximab, a human-mouse chimeric monoclonal antibody that targets B cells, has significantly improved clinical 
outcomes in B-cell lymphoma patients and has been increasingly used in organ transplantation and autoim-
mune diseases5,6,14,15. Despite its potent cytolytic effect, rituximab is generally well tolerated with minimal toxicity; 
however, increasing evidence indicates that rituximab is associated with HBV reactivation16. Therefore, the US 
Food and Drug Administration (FDA) issued a new boxed warning that rituximab increases the risk of HBV 
reactivation17.
Fatal HBV reactivation can occur not only in patients with hematologic malignancy but also in patients with 
kidney transplantation, particularly after receiving rituximab therapy2–4,12. In this study, the risk of HBV reacti-
vation and its severity were found to be associated with the dose of rituximab. Our findings indicate that a stand-
ard dose of rituximab (375 mg/m2) increases the risk of HBV reactivation in HBsAg-negative/anti-HBc-positive 
kidney transplant patients. In contrast, a reduced dose of rituximab (200 mg/body) did not increase the risk of 
HBV reactivation.
The mechanism of rituximab-associated HBV reactivation is not fully understood11. Although control of HBV 
infection is mediated mainly by HBV-specific cytotoxic T cells, B cells are still required for antigen-presentation. 
B-cell depletion by rituximab may disrupt CD8 + cytotoxic T cell killing of HBV-infected hepatocytes18. In addi-
tion, rituximab administration changes T lymphocyte activity by increasing Th1/Th2 and Tc1/Tc2 ratios and 
up-regulating the Fas ligand on Th1 and Th2 cells19.
Considering the net state of immunosuppression, the dose of rituximab may significantly affect HBV reactiva-
tion20. Prior studies demonstrated that patients with advanced malignancy had a higher risk for HBV reactivation, 
possibly because these patients received more cycles of chemotherapy. In contrast, patients with limited-stage 
lymphoma who received fewer cycles of rituximab experienced a reduction in HBV reactivation10. In line with 
previous studies, our data indicate that a standard-dose rituximab significantly increase the risk of HBV reacti-
vation. In addition, standard dose of rituximab may be related to the severity of liver damage21. Among the five 
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Rejection 2.731 (0.653, 11.429) 0.169
Use of ATG 1.509 (0.183, 12.429) 0.702
Standard dose rituximab 8.256 (1.973, 34.551) 0.004 10.598 (2.519, 44.599) 0.001
anti-HBs ≥ 100 IU/L 0.149 (0.018, 1.214) 0.075 0.11 (0.013, 0.905) 0.04
Donor anti-HBc (+) 0.652 (0.132, 3.230) 0.600
Causes of rituximab 0.885 (0.148, 5.297) 0.893
Number of plasmapheresis 1.343 (0.862, 1.913) 0.314
Tacrolimus trough level 0.899 (0.652, 1.240) 0.516
MMF dose 1.001 (0.999,1.002) 0.280
Table 3. Risk factors for HBV reactivation.
Figure 2. Cumulative rates of HBV reactivation. (a) HBV reactivation according to rituximab dose. (b) HBV 
reactivation according to anti-HBs titers at the time of transplantation (anti-HBs < 100 IU/L vs. anti-HBs ≥ 100 
IU/L).
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patients who received a standard dose of rituximab and experienced HBV reactivation, four experienced hepatitis 
flare, including one patient who died from hepatic failure. In contrast, of the three patients with HBV reactivation 
in the control group, only one developed hepatitis flare and none of them died from hepatic failure.
In contrast to patients receiving standard-dose rituximab, none of the patients receiving reduced-dose rituxi-
mab developed HBV reactivation. Recently, Masutani et al. also founded no significant association between HBV 
reactivation and a reduced dose of rituximab in kidney transplant patients13. However, such previous studies, 
including ours, compared a rituximab group with a control group, limiting the interpretation of the effects of 
rituximab dose on the outcomes12,13. The current study design allows us to assess the effect of rituximab dose on 
HBV reactivation more clearly.
The protective role of anti-HBs against HBV reactivation in patients receiving rituximab therapy is contro-
versial22. The FDA reported that HBV reactivation also occurred in patients with anti-HBs20, while other studies 
showed a protective effect of anti-HBs in patients receiving rituximab-based chemotherapy3,4,23. In this study, we 
found that high titers of anti-HBs (≥100 IU/L) at the time of transplantation significantly decreased the risk of 
HBV reactivation (HR, 0.11). In contrast, one patient with a high titer of anti-HBs experienced HBV reactivation 
10 months after receiving a standard dose of rituximab. Accordingly, anti-HBs at the time of rituximab may pro-
vide a protective effect against HBV reactivation, but this association is not absolute23,24.
Another key finding of this study is that rituximab decreases anti-HBs titer in a dose-dependent man-
ner. Although there were differences in baseline anti-HBs titers among groups, our results support the idea 
that a standard dose of rituximab increases the risk of HBV reactivation. Therefore, pre-transplant screening 
for anti-HBs should be included in conjunction with HBsAg and anti-HBc25,26. In patients with low levels of 
anti-HBs, pre-transplant HBV vaccination prior to standard-dose rituximab treatment should be considered. 
Future studies should examine the potential role for booster vaccinations and antiviral prophylaxis according to 
anti-HBs titers23.
Unfortunately, a consensus has not been reached for prophylaxis or monitoring in resolved HBV patients25,26. 
In addition, evaluation of cost-effectiveness is much more complex in an organ transplant setting that require 
life-long immunosuppressive therapy. Although the prevalence of HBV differs across the country, HBV reacti-
vation does occur, and the risk is likely clinically significant27. In this study, the median time from standard-dose 
rituximab desensitization to reactivation was 11 months. Of note, one case of reactivation occurred 22 months 
after rituximab desensitization. On the other hands, the risk of HBV reactivation in the reduced-dose group was 
similar to that in the control group. Our findings suggest that prophylactic antiviral therapy or regular DNA 
monitoring (every 3 months) for 24 months after renal transplantation is important in resolved HBV patients 
receiving a standard dose of rituximab28.
There are several limitations to this study. First, the number of patients with HBV reactivation may have 
been underestimated. The intensity of monitoring can influence the resulting incidence of HBV reactivation22. 
Although ALT and biochemical tests were performed every month for the first year post-transplant, HBV mark-
ers were tested only annually or in patients with elevated ALT. Thus, some asymptomatic HBV reactivation epi-
sodes may have been overlooked. Second, as the desensitization protocol was modified recently, the follow-up 
duration varies among the groups. Although some late HBV reactivation cases have been reported (up to 33 
months after rituximab treatment), most HBV reactivation occurs within one year after rituximab treatment. 
Thus, we think follow-up duration (31.5 months) is sufficient time to see HBV reactivation after reduced-dose 
Figure 3. Changes of anti-HBs titer according to rituximab dose.
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rituximab desensitization29. Third, we noted an imbalance of immunological risk factors among groups, as ritux-
imab dose is determined based on immunological risk. However, HBV reactivation is affected by the “net state 
of immunosuppression”, not by an immunological risk factor itself. Except for desensitization, we maintained 
similar maintenance immunosuppressive regimens and trough levels throughout the study period.
In conclusion, the risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients is significantly related 
to the dose of rituximab. Standard-dose rituximab (375 mg/m2) for desensitization significantly increases the risk 
of HBV reactivation and hepatitis flare and decreases the anti-HBs titer, compared with reduced-dose rituximab 
(200 mg/body) and no rituximab. Close monitoring of HBV DNA and anti-HBs, as well as, the prophylactic or 
preemptive use of antiviral agents should be considered for these patients.
Materials and Methods
Subjects. A total of 957 adult patients who underwent living donor kidney transplantation between 2008 
and 2016 at Severance Hospital in Seoul, Korea were screened. Patients who were both HBsAg-negative and 
anti-HBc-positive were selected. We excluded patients with hepatitis C virus (HCV), follow-up loss, and lack 
of data. Patients were categorized into standard-dose rituximab (375 mg/m2), reduced-dose rituximab (200 mg/
body), and control (no rituximab) groups. In the control group, we excluded patients who were receiving rituxi-
mab for AMR treatment (Fig. 1). All donor surgeries were performed at the same hospital with the consent of the 
donor and approval from the Korean Network Organ Sharing. No allografts (organs and tissue) obtained from 
prisoners were used.
Ethical approval. Written informed consent was obtained from kidney transplant recipients. The study pro-
cedures were conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review 
Board of Severance Hospital (4-2014-1105).
Definitions. We defined resolved HBV infection as HBsAg-negative/anti-HBc-positive patients without HBV 
DNA at the time of transplantation4,30. HBV reactivation was defined as the reemergence of HBsAg (HBsAg ser-
oreversion) or detectable HBV DNA in serum31.
Hepatitis flare was defined as ≥3-fold increase in serum alanine aminotransferase (ALT) levels that exceeded 
100 IU/L. HBV-related hepatitis flare was defined as hepatitis flare with HBV reactivation, in the absence of labo-
ratory features of acute infection with hepatitis A virus, HCV, or cytomegalovirus2.
Monitoring and management of HBV reactivation. All patients were screened for HBV (HBsAg, anti-
body to hepatitis B surface antigen [anti-HBs], anti-HBc, and HBV DNA) and HCV before transplantation. The 
follow-up protocol included the following: (1) routine biochemical tests (including ALT) every month for the 
first year post-transplant and then every 3 months thereafter, (2) assessment of yearly HBV markers (HBsAg and 
anti-HBs), (3) assessment of additional HBsAg for patients with hepatitis flare (serum ALT > 100 IU/L), and (4) 
detection of HBV DNA in cases of HBsAg seroreversion and/or ALT elevation.
Serum HBsAg, anti-HBc, and anti-HBs were evaluated using commercially available enzyme immunoassays 
(Abbott Diagnostics, Abbott Park, IL, USA). Titers of serum anti-HBs < 10 IU/L were considered negative. Serum 
HBV DNA was measured using real-time polymerase chain reaction assay on a Cobas TaqMan 48 Analyzer 
(Roche Molecular Systems, Branchburg, NJ, USA), with 20 IU/mL as the lower limit of detection.
No patients received prophylactic antiviral agents. Entecavir was initiated for patients who experienced HBV 
reactivation.
Immunosuppressive regimen. As previously described, rituximab was administered within 7 days before 
kidney transplantation in cases of ABO-incompatible, positive crossmatch, or high panel reactive antibodies 
(PRA; having a PRA > 50%)32. Since August 2013, our clinic has used a reduced dose of rituximab (200 mg/body) 
based on the patient’s immunological risk (Fig. 4). Plasmapheresis was performed until the target antibody titer 
(IgG titer ≤ 1:16 in ABOi KT, conversion of a positive crossmatch to negative) was achieved.
Most patients received induction immunosuppression with basiliximab (20 mg on day 0 and 4). Since 2013, 
we have used anti-thymocyte globulin (ATG) for induction in positive crossmatch patients (1.5 mg/kg per day 
for 4 days). The maintenance immunosuppressive regimen mostly consisted of calcineurin inhibitor (cyclosporin 
or tacrolimus) and prednisolone with or without MMF. MMF was administered 1 week before transplantation in 
cases of ABOi KT or positive crossmatch KT. We administered calcineurin inhibitor 1 day before or on the day 
of transplantation in all patients, regardless of immunologic risk. The doses of maintenance immunosuppression 
were administered per institutional protocols as previously described29.
Acute cellular rejection (ACR) was treated using methylprednisolone pulse therapy (500 mg/day, three to 
four times). Patients with steroid-resistant ACR patients received ATG. AMR was treated with a combination of 
plasmapheresis and intravenous immunoglobulin with or without rituximab.
Statistical analysis. Data were expressed as frequency (percentage), mean and standard deviation, or 
median and interquartile range, depending on data type. Chi-square or Fisher’s exact tests were used as appro-
priate to compare categorical variables. Continuous variables were compared using one-way analysis of variance. 
When the data revealed a statistically significant difference, post hoc comparisons were performed by applying 
Bonferroni’s correction for multiple comparisons. Cumulative rates of HBV reactivation were analyzed using 
the Kaplan-Meier curves and the log-rank test. Univariate and multivariate analyses were performed using Cox 
proportional hazard regression models to determine risk factors for HBV reactivation. Statistical analyses were 
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performed using SPSS software (version 23.0; SPSS Inc., Chicago, IL, USA), and P < 0.05 was considered statis-
tically significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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